Please select an option below to help us tailor your newsletter to best suit your content interests!
A multicenter, double-blind, placebo-controlled, adaptive phase 3 trial of POL-103A polyvalent melanoma vaccine in post-resection melanoma patients with a high risk of recurrence
A multicenter, double-blind, placebo-controlled, adaptive phase 3 trial of POL-103A polyvalent melanoma vaccine in post-resection melanoma patients with a high risk of recurrence
Stage IIB, IIC, or III Melanoma
Last definitive resection within 90 days of first dose
Complete resection of all known disease
ECOG PS 0-1
Either known BRAF status or 10 unstained slides for BRAF testing
No adjuvant therapy except surgery/radiation, except-
May have had interferon if no longer than 7 days
No use of chronic steroids
Primary- RFS; Secondary- OS